Congenital Diaphragmatic Hernia (CDH)

1. Topic Overview (Clinical Overview)

Congenital Diaphragmatic Hernia (CDH) is a major neonatal surgical emergency characterized by a developmental defect in the diaphragm that allows herniation of abdominal viscera into the thoracic cavity during fetal development. [1] The condition occurs in approximately 1 in 2,500-3,000 live births and remains one of the most challenging congenital anomalies in neonatal medicine, with overall survival rates of 60-80% in specialist centres. [2,3]

The most common type is the Bochdalek hernia (posterolateral defect, ~85% left-sided), which develops due to failure of closure of the pleuroperitoneal canal between 8-10 weeks of gestation. [4] Less commonly, Morgagni hernias (anterior, retrosternal defects) account for ~5% of cases and typically present later in life with milder symptoms. [5]

The clinical significance of CDH lies not in the diaphragmatic defect itself, but in its consequences: pulmonary hypoplasia and pulmonary vascular abnormalities leading to persistent pulmonary hypertension of the newborn (PPHN). [6] The degree of lung underdevelopment—affecting both ipsilateral and contralateral lungs—is the primary determinant of survival and long-term morbidity. Management has evolved dramatically from immediate surgical repair to a "stabilize before surgery" approach, emphasizing gentle ventilation strategies, selective use of ECMO, and delayed surgical repair. [7,8]

Key Clinical Points

Presentation at Birth:

• Scaphoid (sunken) abdomen – pathognomonic sign
• Respiratory distress (cyanosis, tachypnoea, retractions)
• Displaced heart sounds and apex beat
• Absent or diminished breath sounds on affected side
• Bowel sounds may be audible in chest

Critical Management Principles:

• DO NOT bag-mask ventilate – inflates intrathoracic stomach, worsening compression
• Immediate endotracheal intubation and gastric decompression (large-bore NG tube)
• Gentle ventilation strategy – permissive hypercapnia (pH ≥7.20, PaCO₂ 50-65 mmHg)
• Avoid barotrauma – peak inspiratory pressure (PIP) less than 25-28 cmH₂O
• Delayed surgical repair – only after physiological stabilization (24-72+ hours)
• ECMO as rescue therapy for refractory hypoxemia or PPHN

Prognostic Factors:

• Observed/expected lung-to-head ratio (O/E LHR) on antenatal ultrasound [9]
• Liver position (liver herniation = "liver up" = worse prognosis) [10]
• Side of defect (right-sided often worse due to larger defects)
• Presence of associated anomalies (30-50% of cases)
• Timing of symptom onset (earlier = more severe pulmonary hypoplasia)

Why This Matters Clinically

CDH represents a paradigm shift in surgical emergency management. Historical mortality rates exceeded 50% when immediate surgery was the standard approach. [11] Recognition that the primary pathology is pulmonary (not surgical) led to fundamental changes in management strategy. The introduction of gentle ventilation, selective use of inhaled nitric oxide (iNO), and ECMO has improved survival to 70-80% in high-volume centres. [12,13] However, survivors face significant long-term morbidity including chronic lung disease, gastro-oesophageal reflux, failure to thrive, neurodevelopmental delay, and hearing loss. [14]

Antenatal diagnosis (now achieved in 60-80% of cases) allows for planned delivery at tertiary centres with specialized CDH teams, which significantly improves outcomes. [15] The ability to predict severity using fetal imaging parameters (LHR, liver position, total fetal lung volume) enables informed parental counselling and appropriate resource allocation.

---

2. Epidemiology

Incidence and Prevalence

Anatomical Types of CDH

Geographic and Ethnic Variation

CDH incidence shows minimal geographic or ethnic variation, occurring with similar frequency across populations worldwide. [17] However, outcomes vary significantly based on access to specialized perinatal and surgical care.

Associated Anomalies and Syndromes

CDH occurs as an isolated defect in 50-60% of cases, but associated anomalies significantly worsen prognosis. [2]

Associated Structural Anomalies (30-40% of cases):

• Cardiovascular: Ventricular septal defects, atrial septal defects, tetralogy of Fallot, hypoplastic left heart syndrome
• Central nervous system: Neural tube defects, hydrocephalus, anencephaly
• Genitourinary: Renal agenesis, hydronephrosis, cryptorchidism
• Musculoskeletal: Limb reduction defects, omphalocele

Chromosomal Abnormalities (10-20% of cases):

• Trisomy 18 (Edward syndrome)
• Trisomy 13 (Patau syndrome)
• Trisomy 21 (Down syndrome)
• Pallister-Killian syndrome (isochromosome 12p mosaicism)

Genetic Syndromes:

• Fryns syndrome (most common syndromic CDH – facial dysmorphism, distal limb hypoplasia, pulmonary hypoplasia)
• Cornelia de Lange syndrome
• Donnai-Barrow syndrome
• Beckwith-Wiedemann syndrome

Recent Genetic Discoveries: Large-scale genomic studies have identified copy number variants and point mutations in approximately 30% of CDH cases, implicating genes involved in diaphragm development (ZFPM2, GATA4, NR2F2, WT1). [18] This has important implications for genetic counselling and recurrence risk estimation.

---

3. Aetiology and Pathophysiology

Embryological Development of the Diaphragm

The diaphragm develops from four embryonic structures between weeks 4-12 of gestation:

Critical Period for Bochdalek Hernia: The pleuroperitoneal canals (communication between pleural and peritoneal cavities) normally close by 8-10 weeks gestation, with the left side closing slightly later than the right. [4] During this same period (weeks 6-10), the midgut undergoes physiological herniation into the umbilical cord and then returns to the abdominal cavity. If the pleuroperitoneal canal fails to close before the gut returns, abdominal viscera herniate into the thorax, creating a Bochdalek hernia.

Why Left-Sided CDH is More Common:

1. Timing: The left pleuroperitoneal canal closes 1-2 days later than the right
2. Anatomical protection: The liver on the right side provides a physical barrier that prevents or limits right-sided herniation
3. Vascular factors: The right pleuroperitoneal membrane receives earlier vascular supply

Pathophysiology of Pulmonary Hypoplasia

Exam Detail: The pulmonary consequences of CDH develop through a complex cascade:

1. Mechanical Compression (Primary Insult):

• Herniated abdominal viscera (stomach, intestines, spleen, liver) occupy thoracic space
• Direct compression of ipsilateral developing lung
• Mediastinal shift compresses contralateral lung
• Compression occurs during critical period of lung development (canalicular and saccular stages, 16-28 weeks)

2. Structural Lung Abnormalities:

• Reduced alveolar number: Ipsilateral lung has 30-40% of normal alveoli; contralateral lung 60-70% [6]
• Reduced lung weight: Ipsilateral lung often less than 50% expected weight
• Simplified alveolar architecture: Fewer subdivisions, larger primitive saccules
• Deficient surfactant production: Type II pneumocytes reduced in number and function
• Thickened interstitium: Impaired gas exchange

3. Pulmonary Vascular Abnormalities:

• Reduced vessel number: Decreased vascular bed in both lungs
• Vascular remodelling: Abnormal muscularization of peripheral pulmonary arteries
• Medial hypertrophy: Thickened smooth muscle layer extends to smaller, more peripheral vessels than normal
• Adventitial changes: Increased collagen deposition
• Endothelial dysfunction: Reduced nitric oxide synthase expression, impaired vasodilation

These vascular changes create the substrate for persistent pulmonary hypertension of the newborn (PPHN), characterized by:

• Elevated pulmonary vascular resistance (PVR)
• Right-to-left shunting across patent ductus arteriosus (PDA) and foramen ovale (PFO)
• Severe hypoxemia refractory to oxygen supplementation
• Labile oxygenation with minimal stimulation

4. Molecular Mechanisms:

Recent research has identified several molecular pathways implicated in CDH-associated lung hypoplasia: [19,20]

• Retinoic acid signaling: Deficient RA signaling disrupts both diaphragm formation and lung branching morphogenesis
• Fibroblast growth factor (FGF) pathway: Reduced FGF10 expression impairs alveolar development
• Sonic hedgehog (SHH) signaling: Abnormal SHH disrupts mesenchymal-epithelial interactions
• Vascular endothelial growth factor (VEGF): Reduced VEGF contributes to vascular hypoplasia
• Nitric oxide pathway: Decreased endothelial NOS and soluble guanylate cyclase impair pulmonary vasodilation

Pathophysiology at Birth: The Transition Failure

In normal neonates, the transition from fetal to postnatal circulation involves:

1. Lung expansion with first breath → alveolar oxygen tension rises
2. Oxygen triggers pulmonary vasodilation → pulmonary vascular resistance (PVR) drops
3. Left atrial pressure exceeds right atrial pressure → foramen ovale closes
4. Aortic pressure exceeds pulmonary artery pressure → ductus arteriosus constricts
5. Left-to-right flow through ductus → eventual closure

In CDH, this transition fails:

• Hypoplastic lungs cannot expand adequately
• Thickened pulmonary vessels cannot vasodilate normally
• PVR remains suprasystemic
• Right-to-left shunting persists across PDA and PFO
• Severe hypoxemia and acidosis develop rapidly
• Vicious cycle: Hypoxia and acidosis further increase PVR

Gastrointestinal Consequences

• Malrotation: Present in > 80% of CDH cases due to abnormal intestinal rotation during return from physiological umbilical herniation [14]
• Abnormal gastric rotation: Stomach may be abnormally positioned
• Small abdominal cavity: "Loss of domain" – abdominal cavity fails to grow normally because viscera were in chest
• Intestinal compression: Risk of ischemia if herniated bowel is tightly trapped

---

4. Clinical Presentation

Antenatal Diagnosis (60-80% of cases)

With routine second-trimester ultrasound screening, most CDH cases are now diagnosed prenatally, typically at the 18-20 week anomaly scan. [15]

Ultrasound Findings

Prognostic Ultrasound Parameters

Lung-to-Head Ratio (LHR): Measured at 18-24 weeks gestation by comparing lung area to head circumference. [9]

Observed/Expected LHR (O/E LHR): Normalizes LHR for gestational age. O/E LHR less than 25% indicates severe pulmonary hypoplasia with poor prognosis.

Total Fetal Lung Volume (TFLV): Calculated using 3D ultrasound or fetal MRI. O/E TFLV less than 25% associated with mortality > 70%. [9]

Liver Position:

• Liver down (in abdomen): 75-85% survival
• Liver up (herniated into thorax): 45-60% survival [10]

Fetal MRI

Increasingly used to complement ultrasound: [21]

• Superior visualization of lung volumes
• Better delineation of liver position
• Assessment of associated anomalies (particularly CNS)
• Useful in oligohydramnios or poor ultrasound windows

Antenatal Counselling Points

When CDH is diagnosed antenatally, parents should be counselled regarding:

1. Severity prediction based on LHR, liver position, side of defect
2. Associated anomalies – offer detailed fetal echo, karyotype/microarray
3. Planned delivery at tertiary centre with CDH team
4. Likely postnatal course – NICU admission, ventilation, possible ECMO, surgery
5. Outcomes – survival rates, long-term complications
6. Fetal intervention (FETO – see Management section) for severe cases in trial settings

Presentation at Birth (Undiagnosed Cases)

In cases without antenatal diagnosis (now 20-40%), CDH presents with acute respiratory distress immediately after birth or within the first hours of life.

Cardinal Signs

1. Scaphoid (Sunken) Abdomen:

• Most characteristic physical finding
• Abdomen appears flat or concave because abdominal viscera are in chest
• Should prompt immediate suspicion of CDH in any distressed neonate

2. Respiratory Distress:

• Tachypnoea (RR > 60/min)
• Cyanosis (may be severe and refractory to oxygen)
• Nasal flaring, intercostal and subcostal retractions
• Grunting (in severe cases)
• Onset typically within minutes to hours of birth

3. Displaced Heart Sounds:

• Apex beat and maximum heart sounds shifted to opposite side
• In left-sided CDH: Heart sounds loudest on right side
• In right-sided CDH: Heart sounds shifted to left

4. Asymmetric Chest Movement:

• Reduced chest expansion on affected side
• Possible paradoxical movement

5. Absent or Diminished Breath Sounds:

• Markedly reduced air entry on affected side
• Bowel sounds may be audible in chest (specific but not always present)

6. Barrel-Shaped Chest:

• Chest may appear hyperexpanded
• Increased anteroposterior diameter

Timing of Presentation

Late-Presenting CDH

Approximately 5-10% of CDH cases present beyond the neonatal period, even into adulthood. [22] These are typically Morgagni hernias or small Bochdalek defects.

Presentations:

• Recurrent chest infections
• Chronic respiratory symptoms (cough, wheeze, dyspnoea)
• Gastrointestinal symptoms (vomiting, abdominal pain, bowel obstruction)
• Incidental finding on chest X-ray for other indications
• Acute strangulation (rare but life-threatening)

---

5. Investigations

Initial Investigations (Delivery Room / NICU Admission)

Chest X-Ray (Diagnostic Investigation)

Classic Findings:

• Bowel loops in thorax (most specific finding) – gas-filled loops of intestine visible in chest
• NG tube curled in chest – stomach visible above diaphragm
• Mediastinal shift – heart and mediastinum pushed to contralateral side
• Absent diaphragm silhouette on affected side
• Compressed lung – small, atelectatic lung on affected side
• Contralateral lung hypoplasia – may also appear small

Pitfall: Early in life (first 30-60 minutes), bowel may not yet be gas-filled, making diagnosis less obvious. Repeat X-ray after 1-2 hours if clinical suspicion high.

Blood Gas Analysis

Pre-ductal and Post-ductal Saturations:

• Pre-ductal SpO₂ (right hand) and post-ductal SpO₂ (lower limb)
• Difference > 10% suggests significant right-to-left shunting across PDA
• Pre-ductal saturation more accurately reflects brain and coronary perfusion

Arterial Blood Gas: Initial and serial ABGs guide ventilation strategy:

• Assess severity of hypoxemia (PaO₂)
• Monitor permissive hypercapnia (target PaCO₂ 50-65 mmHg)
• Assess acidosis (pH target ≥7.20)
• Lactate as marker of tissue perfusion

Echocardiography

Indications:

• All CDH patients should have echocardiography within first 24 hours

Assessment:

1. Structural heart disease – exclude congenital heart defects (present in 15-20%)
2. Pulmonary hypertension assessment:
   • Tricuspid regurgitation jet velocity (estimate PA pressure)
   • Direction of shunt across PDA and PFO (right-to-left = PPHN)
   • Ventricular septal flattening (indicates RV pressure overload)
   • RV function and dilatation
3. LV function – may be impaired due to LV hypoplasia or secondary to hypoxia
4. Presence and size of PDA – important for understanding shunt physiology

Severity Grading of PPHN on Echo:

• Mild: PA pressure 40-60% of systemic
• Moderate: PA pressure 60-90% of systemic
• Severe: PA pressure > 90% of systemic (suprasystemic)

Antenatal Investigations (If Diagnosed Prenatally)

Investigations to Guide Management

High-Frequency Ventilation Indices

• Oxygenation Index (OI) = (FiO₂ × Mean Airway Pressure × 100) / PaO₂
• OI > 25 on conventional ventilation → consider HFOV
• OI > 40 on HFOV → consider ECMO

ECMO Candidacy Assessment

• Echocardiography to exclude structural heart disease
• Cranial ultrasound to exclude intracranial hemorrhage (contraindication)
• Coagulation profile (bleeding risk assessment)

Investigations for Associated Anomalies

---

6. Management

Delivery Room Resuscitation (Critical First Steps)

The approach in the delivery room is fundamentally different from standard neonatal resuscitation and can be lifesaving if performed correctly.

Immediate Actions

1. DO NOT BAG-MASK VENTILATE This is the single most important initial management point. Positive pressure via bag-mask inflates the intrathoracic stomach and bowel, further compressing already hypoplastic lungs and worsening respiratory failure. [7]

2. Immediate Endotracheal Intubation

• Performed by most experienced practitioner available
• Intubate awake (or with minimal sedation if necessary)
• Avoid hypoxic bradycardic episode during intubation
• Confirm tube position with CO₂ detector and auscultation

3. Insert Large-Bore Orogastric/Nasogastric Tube

• 10-12 Fr double-lumen (Replogle) tube preferred
• Place on continuous low suction (20-40 mmHg)
• Decompress intrathoracic stomach
• Confirm position on X-ray (tube should be visible in chest on initial film)

4. Gentle Ventilation

• Start with low pressures: PIP 20-25 cmH₂O, PEEP 3-5 cmH₂O
• Initial rate 40-60/min
• FiO₂ as required (accept pre-ductal SpO₂ 85-95%)
• Avoid hyperventilation and high pressures – risk of pneumothorax in hypoplastic lungs

5. Monitoring

• Pre-ductal (right hand) and post-ductal (foot) pulse oximetry
• ECG monitoring
• Prepare for umbilical line insertion

6. Minimize Stimulation

• Avoid unnecessary handling
• PPHN can worsen dramatically with agitation
• Consider early sedation ± muscle relaxation

NICU Stabilization Phase

The goal is physiological stabilization before surgical repair – "stabilize the physiology, then fix the anatomy." [8]

Ventilation Strategy: Gentle Ventilation with Permissive Hypercapnia

Exam Detail: Conventional Mechanical Ventilation:

• Mode: Pressure-controlled ventilation or synchronized intermittent mandatory ventilation (SIMV)
• PIP: 20-25 cmH₂O (maximum 28 cmH₂O) – minimize volutrauma
• PEEP: 3-5 cmH₂O – maintain functional residual capacity without overdistension
• Rate: 40-60/min initially
• Inspiratory time: 0.3-0.5 seconds
• FiO₂: Titrate to pre-ductal SpO₂ 85-95%

Permissive Hypercapnia Targets: [7,8]

• pH: 7.20-7.35 (accept ≥7.15 if stable)
• PaCO₂: 50-65 mmHg (accept up to 70 mmHg if pH > 7.20)
• PaO₂: 40-70 mmHg pre-ductal (avoid hyperoxia)

Rationale:

• Hypoplastic lungs are extremely vulnerable to barotrauma and volutrauma
• Aggressive ventilation increases pneumothorax risk and worsens lung injury
• Permissive hypercapnia reduces ventilator-induced lung injury
• Studies show improved survival with gentle ventilation vs. aggressive approaches [7]

High-Frequency Oscillatory Ventilation (HFOV):

• Indications: OI > 25-30 on conventional ventilation, air leak, severe PPHN
• Settings:
  • "Mean airway pressure (MAP): Start 2-3 cmH₂O above MAP on conventional ventilation"
  • "Frequency: 10-15 Hz (for neonates)"
  • "Amplitude (ΔP): Titrate to achieve visible chest wiggle"
  • "FiO₂: As required for target saturations"

Management of Persistent Pulmonary Hypertension (PPHN)

1. Inhaled Nitric Oxide (iNO):

• First-line pulmonary vasodilator for PPHN [13]
• Dose: Start at 20 ppm (parts per million)
• Titrate down to lowest effective dose (typically 5-10 ppm)
• Assess response after 30-60 minutes (improvement in OI by > 20%)
• Wean gradually when improving (risk of rebound PPHN if stopped abruptly)
• Approximately 50% of CDH patients respond to iNO

2. Inotropic Support:

• Milrinone: Phosphodiesterase-3 inhibitor
  • Reduces PVR (pulmonary vasodilation)
  • Increases cardiac contractility
  • "Dose: Loading 50 mcg/kg over 30 min, then infusion 0.5-0.75 mcg/kg/min"
  • First-line inotrope in CDH with PPHN
• Dopamine: 5-10 mcg/kg/min for systemic blood pressure support
• Dobutamine: 5-10 mcg/kg/min for inotropy
• Norepinephrine/Epinephrine: For refractory hypotension

Goal: Maintain systemic blood pressure above pulmonary artery pressure to minimize right-to-left shunting.

3. Sedation and Muscle Relaxation:

• Reduces oxygen consumption and stress response
• Prevents "fighting" the ventilator (increases PVR)
• Fentanyl infusion: 1-5 mcg/kg/h
• Midazolam infusion: 0.05-0.2 mg/kg/h
• Vecuronium or rocuronium: If muscle relaxation needed (0.05-0.1 mg/kg/h)

4. Optimize Cardiovascular Physiology:

• Maintain adequate preload (CVP 6-10 mmHg)
• Correct anemia (target Hb > 13 g/dL in first week)
• Maintain normothermia (hypothermia increases PVR)
• Correct metabolic acidosis (pH > 7.20)
• Maintain normoglycemia

5. Sildenafil:

• Phosphodiesterase-5 inhibitor (pulmonary vasodilator)
• Dose: 0.5-2 mg/kg PO/NG every 6-8 hours
• Typically used as second-line or for weaning off iNO
• May be continued long-term in chronic pulmonary hypertension

Supportive Care

Nutritional Support:

• NPO (nil by mouth) initially
• Early parenteral nutrition (within 24 hours)
• Target caloric intake 100-120 kcal/kg/day
• Delay enteral feeds until after surgery and stable

Fluid Management:

• Restrict to 60-80% maintenance in first 72 hours
• Monitor urine output (target 1-2 mL/kg/h)
• Avoid fluid overload (worsens pulmonary edema and PPHN)

Infection Prophylaxis:

• Broad-spectrum antibiotics until sepsis excluded (ampicillin + gentamicin)

Stress Ulcer Prophylaxis:

• Ranitidine or omeprazole

Extracorporeal Membrane Oxygenation (ECMO)

Indications for ECMO in CDH

Types of ECMO:

• Veno-arterial (VA) ECMO: Provides cardiac and respiratory support (preferred in CDH)
• Veno-venous (VV) ECMO: Respiratory support only (rarely used in CDH due to PPHN and cardiac dysfunction)

ECMO Outcomes in CDH

• Approximately 30-40% of CDH patients require ECMO [12,13]
• Survival to discharge: 50-60% of those cannulated
• Duration: Typically 7-14 days (longer runs associated with worse outcomes)
• Complications: Bleeding (especially intracranial hemorrhage), infection, thrombosis, neurological injury

Contraindications to ECMO

Absolute:

• Intracranial hemorrhage (Grade III-IV)
• Severe congenital heart disease incompatible with life
• Lethal chromosomal anomaly (e.g., Trisomy 13, 18)
• Gestational age less than 34 weeks (relative)
• Birth weight less than 1.8-2.0 kg (relative)

Relative:

• Prolonged mechanical ventilation (> 10-14 days) with high settings
• Severe lung hypoplasia (O/E LHR less than 15%)

Surgical Repair

Timing: Delayed Repair Strategy

Traditional Approach (Pre-1990s):

• Immediate surgery (within hours of birth)
• Rationale: "Surgical emergency – fix the hole"
• Outcome: High mortality (> 50%)

Current Approach:

• Delayed repair after stabilization (typically 24-72 hours, often longer) [8,11]
• Rationale: Primary pathology is pulmonary; surgery adds physiological stress
• Wait until:
  • Stable on ventilator (FiO₂ less than 0.5, PIP less than 25 cmH₂O) for 24-48 hours
  • PPHN improving (reducing iNO, stable hemodynamics)
  • Normal or near-normal lactate
  • No increasing inotropic requirements
• Some centres wait 7-10 days or longer for "super-stable" approach

Evidence: Multiple studies demonstrate improved survival with delayed vs. immediate surgery (70-80% vs. 50-60%). [11]

Surgery on ECMO: Controversial. Some centres perform repair on ECMO for patients who cannot wean; others wait until patient can be decannulated. Outcomes are worse for on-ECMO repair but may be due to patient selection (sicker patients).

Surgical Techniques

Approach:

• Abdominal (transabdominal): Most common – subcostal or transverse incision
• Thoracic (thoracotomy): For large defects, better visualization of intrathoracic structures
• Thoracoscopic/Laparoscopic: Increasingly used for smaller defects (minimally invasive)

Procedure Steps:

1. Reduce herniated viscera back into abdomen
2. Assess diaphragm defect size
3. Close defect:
   • Primary closure: Possible for small defects (less than 2-3 cm) – suture edges of diaphragm directly
   • Patch repair: Required for large defects – use Gore-Tex, PTFE, or biosynthetic mesh

Patch vs. Primary Repair:

• Primary repair: Lower recurrence rate (~5-10%)
• Patch repair: Higher recurrence rate (~10-20%) but necessary for large defects

Additional Procedures:

• Ladd procedure (division of Ladd bands) if malrotation present (> 80% of cases)
• Creation of gastrostomy tube for feeding (controversial – some centres advocate, others avoid)

Complications of Surgery:

• Recurrence (5-20% depending on technique)
• Wound infection
• Intestinal obstruction (adhesions)
• Patch infection (if synthetic patch used)
• Scoliosis/chest wall deformity (late complication)

Fetal Intervention: Fetal Endoscopic Tracheal Occlusion (FETO)

For severe CDH diagnosed antenatally (O/E LHR less than 25%, liver up), some centres offer experimental fetal therapy.

FETO Procedure: [15,21]

• Fetoscopic placement of balloon in fetal trachea at 27-30 weeks gestation
• Balloon occludes trachea → lung fluid accumulates → lungs expand → stimulates lung growth
• Balloon removed at 34 weeks (second fetoscopy) to allow normal lung development before birth

Evidence:

• TOTAL trial (2021): Showed improved survival in severe left-sided CDH (40% vs. 15% in expectant management) [21]
• Still considered experimental; not standard of care in most countries
• Offered only in specialized fetal therapy centres within research protocols

Risks:

• Preterm prelabour rupture of membranes (PPROM)
• Preterm delivery
• Fetal or maternal complications from fetoscopy

---

7. Prognosis and Outcomes

Survival Rates

Historical Context: Survival has improved from less than 50% in the 1980s to 70-80% currently in high-volume specialist centres, due to:

• Gentle ventilation strategies
• Selective use of iNO and ECMO
• Delayed surgical repair
• Centralization of care to specialized centres [7,8,11]

Prognostic Factors

Antenatal Predictors (Poor Prognosis)

Postnatal Predictors (Poor Prognosis)

Long-Term Complications and Morbidities

Survival is not the end of the story – CDH survivors face significant long-term morbidity requiring multidisciplinary follow-up. [14]

Respiratory Complications

Follow-up: Pulmonary function tests at school age often show restrictive pattern (reduced FVC and TLC) due to chest wall deformity and lung hypoplasia.

Gastrointestinal Complications

Musculoskeletal Complications

Neurodevelopmental Outcomes

Follow-up: All CDH survivors should have developmental assessment at 2 years and school entry; audiology screening at 6-12 months and then annually.

Hernia Recurrence

• Occurs in 5-10% after primary repair, 10-20% after patch repair [14]
• Typically presents within first 2 years
• May present with respiratory symptoms, bowel obstruction, or incidental finding on imaging
• Requires re-operation

Long-Term Follow-Up

Multidisciplinary CDH Follow-Up Clinic: Most tertiary centres run specialized CDH clinics involving:

• Paediatric surgery
• Respiratory medicine
• Gastroenterology
• Audiology
• Developmental pediatrics
• Nutrition/dietetics
• Physiotherapy/occupational therapy

Recommended Schedule:

• 3, 6, 12 months, then annually until transition to adult services
• More frequent if complications

Investigations:

• Serial echocardiograms (years 1, 2, 5 – assess residual pulmonary hypertension)
• Audiology (6 months, 12 months, annually)
• Developmental screening (2 years, school entry)
• Pulmonary function tests (from age 6-7 years)
• Chest X-ray (assess scoliosis, recurrence)

---

8. Classification Systems

Anatomical Classification of CDH

CDH Study Group Staging System

The international CDH Study Group uses staging to predict outcome and guide treatment: [12]

Severity Grading Based on Antenatal Imaging

---

9. Key Guidelines and Evidence

Major Guidelines

Key Evidence Base

1. Delayed Surgery vs. Immediate Surgery:

• Multiple retrospective cohort studies and registry analyses show improved survival with delayed repair (> 24 hours after birth) compared to immediate repair
• Survival improved from ~50% (immediate surgery era) to 70-80% (delayed surgery era) [11]

2. Gentle Ventilation and Permissive Hypercapnia:

• Retrospective studies show reduced barotrauma and improved outcomes
• Target pH ≥7.20, PaCO₂ 50-65 mmHg, PIP less than 25-28 cmH₂O [7]

3. Inhaled Nitric Oxide in CDH:

• Cochrane review (2016): No clear mortality benefit, but may improve oxygenation and reduce need for ECMO in responders
• Approximately 50% respond to iNO [13]

4. ECMO in CDH:

• Large registry studies (ELSO – Extracorporeal Life Support Organization):
  • ~35% of CDH patients require ECMO
  • "Survival to discharge: 50-60% for ECMO patients"
  • "Main complications: Intracranial hemorrhage (10-15%), infection, bleeding [12]"

5. Fetal Endoscopic Tracheal Occlusion (FETO):

• TOTAL trial (2021): For severe left-sided CDH (O/E LHR less than 25%), FETO improved survival (40% vs. 15% expectant management) [21]
• Increased risk of preterm birth (PPROM)
• Ongoing trials for right-sided and moderate CDH

6. Centralized Care:

• Studies show improved outcomes at high-volume centres (> 10 cases/year) vs. low-volume centres
• Antenatal diagnosis and planned delivery at tertiary centre improve survival by 15-20% [15]

---

10. Examination Focus

High-Yield Viva Topics

Opening Statement for CDH

Model Answer: "Congenital Diaphragmatic Hernia is a developmental defect of the diaphragm, most commonly posterolateral (Bochdalek type), that allows herniation of abdominal viscera into the thorax during fetal development. It occurs in approximately 1 in 2,500-3,000 live births. The key pathophysiology is pulmonary hypoplasia and abnormal pulmonary vascular development, leading to persistent pulmonary hypertension of the newborn. Management has evolved from immediate surgical repair to a stabilize-first approach with gentle ventilation, permissive hypercapnia, selective use of inhaled nitric oxide and ECMO, followed by delayed surgical repair once the infant is stable. Overall survival is 70-80% in specialized centres for isolated CDH."

Common Exam Questions with Model Answers

Q1: A baby is born at term with a scaphoid abdomen and severe respiratory distress. What is your differential diagnosis and immediate management?

Model Answer: "The scaphoid abdomen and respiratory distress strongly suggest Congenital Diaphragmatic Hernia. My differential would include:

1. CDH (most likely given scaphoid abdomen)
2. Severe respiratory distress syndrome (but scaphoid abdomen unusual)
3. Congenital pneumonia/sepsis
4. Tension pneumothorax

Immediate management:

• Do NOT bag-mask ventilate – this will inflate the intrathoracic stomach and worsen pulmonary compression
• Immediate endotracheal intubation by the most experienced clinician
• Insert large-bore NG/OG tube on continuous suction to decompress stomach
• Gentle ventilation with low pressures (PIP 20-25 cmH₂O, PEEP 3-5)
• Pre-ductal and post-ductal oxygen saturation monitoring
• Urgent chest X-ray – will show bowel loops in chest, mediastinal shift
• IV access, bloods including blood gas, transfer to NICU
• Inform paediatric surgery and neonatal team"

---

Q2: What is the pathophysiology of pulmonary hypoplasia in CDH?

Model Answer: "Pulmonary hypoplasia in CDH results from compression of the developing lungs by herniated abdominal viscera during the critical canalicular and saccular stages of lung development (16-28 weeks gestation).

Structural consequences:

• Reduced number of alveoli (ipsilateral lung 30-40% of normal, contralateral 60-70%)
• Simplified alveolar architecture
• Thickened interstitium impairing gas exchange
• Deficient surfactant production

Vascular consequences:

• Reduced pulmonary vascular bed
• Abnormal muscularization of peripheral pulmonary arteries (medial hypertrophy extending to small vessels)
• Endothelial dysfunction with reduced nitric oxide synthase expression

These changes create the substrate for persistent pulmonary hypertension of the newborn (PPHN), with elevated pulmonary vascular resistance, right-to-left shunting across the PDA and foramen ovale, and severe hypoxemia.

The critical point is that both lungs are affected – the contralateral lung is also hypoplastic, though to a lesser degree. This is why mortality is primarily determined by the degree of lung hypoplasia, not the diaphragmatic defect itself."

---

Q3: Why has management shifted from immediate to delayed surgical repair in CDH?

Model Answer: "This represents a fundamental paradigm shift in understanding CDH pathophysiology.

Old approach (pre-1990s):

• CDH viewed as a surgical emergency
• Immediate repair (within hours of birth)
• Rationale: 'Fix the hole to allow lungs to expand'
• Outcome: Mortality > 50%

Current understanding:

• The primary pathology is pulmonary (hypoplasia and PPHN), not surgical
• The neonate is in a critical transitional state with labile pulmonary pressures
• Surgery adds significant physiological stress (anesthesia, blood loss, pain, increased metabolic demand)
• Aggressive ventilation to prepare for immediate surgery caused barotrauma

New approach (current standard):

• Delay surgery for 24-72 hours (or longer) until stabilized
• Focus on gentle ventilation, treating PPHN, hemodynamic support
• Operate only when FiO₂ less than 0.5, stable pressures, weaning inotropes, normal lactate
• Some centres advocate 'super-delayed' repair at 7-10+ days

Evidence: Multiple retrospective studies show improved survival from ~50% to 70-80% with delayed approach. The surgical defect can wait – the lungs cannot be rushed."

---

Q4: What are the indications for ECMO in a neonate with CDH, and what are the outcomes?

Model Answer: "ECMO is considered rescue therapy for CDH when maximal medical management has failed.

Indications:

• Oxygenation Index (OI) > 40 for 3-4 hours despite maximal therapy
  • OI = (FiO₂ × Mean Airway Pressure × 100) / PaO₂
• Severe hypoxemia: Pre-ductal PaO₂ less than 40 mmHg on FiO₂ 1.0
• Refractory acidosis: pH less than 7.15 despite treatment
• Decompensated shock: Despite inotropic support, lactate > 10 mmol/L

Contraindications:

• Intracranial hemorrhage (Grade III-IV)
• Lethal chromosomal anomaly
• Gestational age less than 34 weeks (relative)
• Weight less than 1.8-2.0 kg (relative)

Type: VA-ECMO (veno-arterial) preferred as it provides both cardiac and respiratory support.

Outcomes:

• Approximately 30-40% of CDH patients require ECMO
• Survival to discharge: 50-60% (compared to 80-90% for non-ECMO CDH)
• Duration typically 7-14 days (longer runs have worse outcomes)
• Major complications:
  • Intracranial hemorrhage (10-15%)
  • Infection
  • Bleeding
  • Long-term neurodevelopmental impairment

ECMO is lifesaving for some but carries significant risks. Patient selection is critical."

---

Q5: What antenatal ultrasound parameters predict severity in CDH?

Model Answer: "Several antenatal parameters help predict severity and counsel parents:

1. Lung-to-Head Ratio (LHR):

• Measured at 18-24 weeks by comparing area of contralateral lung to head circumference
• Observed/Expected LHR (O/E LHR) normalizes for gestational age
  • "O/E LHR > 45%: Mild (survival > 80%)"
  • "O/E LHR 25-45%: Moderate (survival 50-75%)"
  • "O/E LHR less than 25%: Severe (survival 15-40%)"

2. Liver Position:

• Liver down (in abdomen): 75-85% survival
• Liver up (herniated into thorax): 45-60% survival
• Indicates larger defect and greater mass effect

3. Total Fetal Lung Volume (TFLV):

• Measured by 3D ultrasound or fetal MRI
• O/E TFLV less than 25% associated with very poor prognosis

4. Side of Defect:

• Left-sided: More common, slightly better prognosis
• Right-sided: Often larger defects, liver herniation more likely, worse outcomes

5. Other factors:

• Associated anomalies (significantly worsen prognosis)
• Polyhydramnios (suggests esophageal compression)
• Early diagnosis (less than 24 weeks) may indicate more severe defect

These parameters guide:

• Parental counselling
• Consideration of FETO (fetal therapy) for severe cases
• Planning delivery at specialized centre with ECMO capability"

---

Q6: Describe the 'gentle ventilation' strategy in CDH and its rationale.

Model Answer: "Gentle ventilation with permissive hypercapnia is the cornerstone of modern CDH respiratory management.

Principles:

• Low peak inspiratory pressure (PIP): 20-25 cmH₂O, maximum 28 cmH₂O
• Moderate PEEP: 3-5 cmH₂O
• Permissive hypercapnia: Accept PaCO₂ 50-65 mmHg (up to 70 mmHg)
• Permissive acidosis: Accept pH ≥7.20 (some centres ≥7.15)
• Moderate oxygenation targets: Pre-ductal SpO₂ 85-95%, PaO₂ 40-70 mmHg
• Avoid hyperventilation and hyperoxia

Rationale:

1. Hypoplastic lungs are fragile: Vulnerable to barotrauma and volutrauma
2. Reduced alveolar surface area: Requires high pressures to achieve normocapnia → barotrauma
3. Risk of pneumothorax: Aggressive ventilation increases air leak risk
4. Ventilator-induced lung injury: High pressures cause inflammatory cascade
5. Hyperoxia is harmful: Generates reactive oxygen species, worsens lung injury

Evidence: Retrospective studies comparing aggressive vs. gentle ventilation show:

• Reduced pneumothorax rates
• Reduced chronic lung disease
• Improved survival (from ~50% to 70-80%)

Escalation: If failing gentle conventional ventilation (OI > 25-30):

• High-frequency oscillatory ventilation (HFOV)
• Inhaled nitric oxide for PPHN
• ECMO if OI > 40

The key message: Accept some degree of hypercapnia and hypoxia to protect the lungs."

---

Q7: What are the long-term complications in CDH survivors?

Model Answer: "CDH survivors face significant long-term morbidity requiring multidisciplinary follow-up.

Respiratory complications (most common):

• Chronic lung disease: 30-50% – require home oxygen, bronchodilators
• Recurrent respiratory infections: 40-60%
• Reactive airway disease/asthma: 30-40%
• Exercise intolerance: 50-70%
• Persistent pulmonary hypertension: 10-20% – may need long-term sildenafil
• Restrictive lung function on testing (reduced FVC, TLC)

Gastrointestinal complications:

• Gastro-oesophageal reflux (GORD): 50-70% – may require fundoplication
• Feeding difficulties and oral aversion: 40-60%
• Failure to thrive: 30-40%
• Intestinal obstruction: 10-15% (adhesions)

Musculoskeletal:

• Scoliosis: 20-40% (especially after patch repair)
• Pectus deformity: 20-30%
• Chest wall asymmetry

Neurodevelopmental:

• Developmental delay: 20-40% (higher in ECMO survivors)
• Hearing loss: 10-30% (ototoxic drugs, ECMO)
• Cognitive impairment: 15-30%

Surgical:

• Hernia recurrence: 5-10% (primary repair), 10-20% (patch repair)

Follow-up strategy:

• Multidisciplinary CDH clinic (surgery, respiratory, GI, audiology, developmental)
• Serial echocardiograms (assess pulmonary hypertension)
• Audiology screening (6, 12 months, then annual)
• Developmental assessment (2 years, school entry)
• Pulmonary function tests from age 6-7 years

Survival is not the end – quality of life and long-term outcomes require ongoing attention."

---

Common Pitfalls and Mistakes

❌ DON'T:

• Bag-mask ventilate a baby with suspected CDH (inflates intrathoracic stomach)
• Aim for normal blood gases (causes barotrauma to hypoplastic lungs)
• Rush to immediate surgery (worsens outcomes)
• Use high ventilator pressures (increases pneumothorax risk)
• Forget to assess for associated anomalies (present in 30-50%)
• Assume good short-term outcome means no long-term issues (many complications emerge over years)

✓ DO:

• Immediate intubation (not bag-mask) for respiratory distress with scaphoid abdomen
• Insert large-bore NG tube on continuous suction
• Accept permissive hypercapnia (pH ≥7.20, PaCO₂ 50-65 mmHg)
• Delay surgery until stabilized (24-72+ hours)
• Use pre-ductal and post-ductal saturations to assess shunting
• Arrange echocardiography to assess PPHN and exclude cardiac anomalies
• Involve multidisciplinary team early
• Ensure long-term follow-up for respiratory, GI, developmental, hearing issues

---

11. Patient/Layperson Explanation

What is Congenital Diaphragmatic Hernia?

Congenital Diaphragmatic Hernia (CDH) is a birth defect where a baby is born with a hole in the diaphragm – the muscle that separates the chest from the tummy (abdomen). This hole forms very early in pregnancy, around 8-10 weeks, and allows some of the organs from the tummy (like the intestines, stomach, and sometimes the liver) to move up into the chest before the baby is born.

Why is this a problem?

When the tummy organs are in the chest, they take up space where the lungs should be growing. This means the lungs don't develop properly – they're smaller than normal and don't work as well. This is called "pulmonary hypoplasia" (under-developed lungs). The lungs also have problems with their blood vessels, which can lead to high blood pressure in the lung vessels (pulmonary hypertension).

When the baby is born and tries to breathe, the small, underdeveloped lungs struggle to provide enough oxygen to the body.

How common is CDH?

CDH occurs in about 1 in every 2,500-3,000 babies born. Most cases (about 85%) are on the left side. About 60-80% of cases are now detected during pregnancy on the 20-week ultrasound scan.

What are the symptoms?

Babies with CDH usually show symptoms very soon after birth:

• Difficulty breathing (fast breathing, blue color, grunting sounds)
• Sunken or flat tummy (called a "scaphoid abdomen") – because the tummy organs are in the chest
• Heart sounds in an unusual place – the heart may be pushed to the opposite side of the chest

Some babies with very small holes may not have symptoms at birth and may be diagnosed later in childhood or even adulthood.

How is CDH diagnosed?

Before birth:

• Most cases are found on the routine ultrasound scan at around 20 weeks of pregnancy
• The scan may show the stomach or intestines in the chest instead of the tummy
• Further scans and MRI may be done to assess how severe the problem is

After birth:

• Chest X-ray showing bowel loops in the chest confirms the diagnosis
• An ultrasound of the heart (echocardiogram) checks for other problems and measures blood pressure in the lungs

How is CDH treated?

Immediately after birth:

1. Breathing tube inserted: Your baby will need a tube inserted into their windpipe (intubation) to help them breathe. It's very important NOT to use a face mask to help breathing, as this pushes air into the stomach and makes things worse.
2. Tube into the stomach: A tube is passed through the nose or mouth into the stomach to remove air and fluid.
3. Breathing machine (ventilator): Your baby will be connected to a ventilator that helps them breathe gently without damaging the small lungs.

In the Neonatal Intensive Care Unit (NICU):

• Gentle ventilation: Doctors use low pressures on the breathing machine and accept higher carbon dioxide levels than normal to avoid damaging the lungs.
• Medicine for lung blood pressure: A gas called nitric oxide may be breathed in through the breathing tube to help relax the blood vessels in the lungs.
• Medicine to support the heart: Your baby may need medicines to help the heart pump and maintain blood pressure.
• ECMO (heart-lung machine): If your baby's lungs are very severely affected and can't provide enough oxygen despite all treatments, a machine called ECMO may be used. This takes blood out of the body, adds oxygen, removes carbon dioxide, and returns it to the body – giving the lungs time to recover. About 30-40% of babies with CDH need ECMO.

Surgery: Once your baby is stable (usually after 1-3 days, sometimes longer), an operation is performed to:

• Put the organs back into the tummy
• Close the hole in the diaphragm

For small holes, the edges can be stitched together. For larger holes, a patch (usually made of a material called Gore-Tex) is sewn in to cover the hole.

Why isn't surgery done immediately? Years ago, doctors operated as soon as possible after birth. However, it was discovered that waiting until the baby is more stable leads to much better survival. The main problem is the small lungs, not the hole itself. Surgery adds extra stress to a very sick baby, so it's better to wait until they're stronger.

What is the outcome?

Survival:

• Overall, about 70-80% of babies with CDH survive in specialist centres
• The outcome depends on how severe the lung underdevelopment is
• Babies with CDH alone (no other problems) have a better outcome than those with heart or chromosome problems

Long-term health: Many babies who survive CDH have ongoing health issues and need long-term follow-up:

• Lung problems: 30-50% have chronic lung disease and may need oxygen at home, inhalers, or medicines. They may have more chest infections and asthma.
• Feeding and tummy problems: 50-70% have reflux (stomach acid coming back up) and may have difficulty feeding or gaining weight.
• Developmental delay: 20-40% may have some delay in reaching developmental milestones.
• Hearing loss: 10-30% may have hearing problems, so hearing tests are done regularly.
• Hernia coming back: 5-20% may have the hernia come back and need another operation.

Follow-up care: Your child will need regular check-ups with a specialist team including:

• Surgeons
• Lung doctors
• Stomach/feeding specialists
• Hearing specialists
• Developmental specialists
• Dietitians and therapists

Can CDH be treated before birth?

For very severe cases diagnosed during pregnancy, some specialist centres offer an experimental treatment called FETO (Fetal Endoscopic Tracheal Occlusion):

• A tiny balloon is placed in the baby's windpipe at around 27-30 weeks of pregnancy
• This blocks fluid from leaving the lungs, which helps them grow larger
• The balloon is removed before birth

Research has shown this can improve survival in the most severe cases, but it's still considered experimental and is only done in a few specialist centres as part of research studies.

What support is available?

CDH UK (Charity): Provides information and support for families affected by CDH

• Website: www.cdhuk.org.uk
• Helpline and parent support network
• Information leaflets and resources

Key Messages for Parents

1. Specialist care is essential: Your baby needs care at a specialist centre with experience in CDH.
2. Modern treatment has improved survival: With current treatment, 70-80% of babies survive.
3. Every baby is different: The severity varies greatly – some babies do very well, others face more challenges.
4. Long-term follow-up is important: Even babies who do well initially may develop problems later.
5. Support is available: You are not alone – connect with other families through support groups.

Questions to Ask Your Doctor

• How severe is my baby's CDH?
• What is the predicted outcome based on the scans?
• Will my baby need ECMO?
• What long-term problems might my child have?
• What follow-up will be needed?
• Where can I get support?

---

12. References

1. Longoni M, High FA, Qi H, Joy MP, Hila R, Coletti CM, et al. Genome-wide enrichment of damaging de novo variants in patients with isolated and complex congenital diaphragmatic hernia. Hum Genet. 2017;136(6):679-691. doi:10.1007/s00439-017-1774-y

2. Lally KP, Lasky RE, Lally PA, Bagolan P, Davis CF, Frenckner BP, et al. Standardized reporting for congenital diaphragmatic hernia--an international consensus. J Pediatr Surg. 2013;48(12):2408-2415. doi:10.1016/j.jpedsurg.2013.08.014

3. Wynn J, Krishnan U, Aspelund G, Zhang Y, Duong J, Stolar CJ, et al. Outcomes of congenital diaphragmatic hernia in the modern era of management. J Pediatr. 2013;163(1):114-119.e1. doi:10.1016/j.jpeds.2012.12.036

4. Kardon G, Ackerman KG, McCulley DJ, Shen Y, Wynn J, Shang L, et al. Congenital diaphragmatic hernias: from genes to mechanisms to therapies. Dis Model Mech. 2017;10(8):955-970. doi:10.1242/dmm.028365

5. Bohn D. Congenital diaphragmatic hernia. Am J Respir Crit Care Med. 2002;166(7):911-915. doi:10.1164/rccm.200204-302CC

6. Keijzer R, Puri P. Congenital diaphragmatic hernia. Semin Pediatr Surg. 2010;19(3):180-185. doi:10.1053/j.sempedsurg.2010.03.001

7. Snoek KG, Reiss IKM, Greenough A, Capolupo I, Urlesberger B, Wessel L, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus - 2015 update. Neonatology. 2016;110(1):66-74. doi:10.1159/000444210

8. Puligandla PS, Skarsgard ED, Offringa M, Adatia I, Baird R, Bailey M, et al. Diagnosis and management of congenital diaphragmatic hernia: a clinical practice guideline. CMAJ. 2018;190(4):E103-E112. doi:10.1503/cmaj.170206

9. Jani JC, Nicolaides KH, Gratacós E, Valencia CM, Doné E, Martinez JM, et al. Severe diaphragmatic hernia treated by fetal endoscopic tracheal occlusion. Ultrasound Obstet Gynecol. 2009;34(3):304-310. doi:10.1002/uog.6450

10. Mullassery D, Ba'ath ME, Jesudason EC, Losty PD. Value of liver herniation in prediction of outcome in fetal congenital diaphragmatic hernia: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2010;35(5):609-614. doi:10.1002/uog.7586

11. Javid PJ, Jaksic T, Skarsgard ED, Lee S; Canadian Neonatal Network. Survival rate in congenital diaphragmatic hernia: the experience of the Canadian Neonatal Network. J Pediatr Surg. 2004;39(5):657-660. doi:10.1016/j.jpedsurg.2004.01.022

12. Tsao K, Lally PA, Lally KP; Congenital Diaphragmatic Hernia Study Group. Minimally invasive repair of congenital diaphragmatic hernia. J Pediatr Surg. 2011;46(6):1158-1164. doi:10.1016/j.jpedsurg.2011.03.050

13. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics. 1997;99(6):838-845. doi:10.1542/peds.99.6.838

14. Chiu PP, Sauer C, Mihailovic A, Adatia I, Bohn D, Coates AL, et al. The price of success in the management of congenital diaphragmatic hernia: is improved survival accompanied by an increase in long-term morbidity? J Pediatr Surg. 2006;41(5):888-892. doi:10.1016/j.jpedsurg.2006.01.026

15. Colvin J, Bower C, Dickinson JE, Sokol J. Outcomes of congenital diaphragmatic hernia: a population-based study in Western Australia. Pediatrics. 2005;116(3):e356-e363. doi:10.1542/peds.2004-2845

16. Pober BR. Overview of epidemiology, genetics, birth defects, and chromosome abnormalities associated with CDH. Am J Med Genet C Semin Med Genet. 2007;145C(2):158-171. doi:10.1002/ajmg.c.30126

17. Yang W, Carmichael SL, Harris JA, Shaw GM. Epidemiologic characteristics of congenital diaphragmatic hernia among 2.5 million California births, 1989-1997. Birth Defects Res A Clin Mol Teratol. 2006;76(3):170-174. doi:10.1002/bdra.20230

18. Qi BQ, Beasley SW, Frizelle FA. Clarification of the processes that lead to fetal gut herniation and return in the rat model of CDH. Pediatr Surg Int. 2003;19(1-2):6-11. doi:10.1007/s00383-002-0898-z

19. Montalva L, Zani A. Assessment of the nitric oxide pathway in congenital diaphragmatic hernia. Eur J Pediatr Surg. 2015;25(6):443-449. doi:10.1055/s-0035-1569465

20. Takayasu H, Masumoto K, Jimbo T, Komura H, Aoki M, Ono K, et al. Analysis of risk factors of long-term complications in congenital diaphragmatic hernia: a single institution's experience. Asian J Surg. 2019;42(12):860-865. doi:10.1016/j.asjsur.2019.01.012

21. Deprest JA, Nicolaides KH, Benachi A, Gratacos E, Ryan G, Persico N, et al. Randomized trial of fetal surgery for severe left diaphragmatic hernia. N Engl J Med. 2021;385(2):107-118. doi:10.1056/NEJMoa2027030

22. Brown RA, Millar AJW. Morgagni hernia in childhood. Semin Pediatr Surg. 2017;26(6):413-416. doi:10.1053/j.sempedsurg.2017.11.011

---

Medical Disclaimer: This content is for educational purposes and clinical reference. It should not replace clinical judgment or individualized patient care. Always consult current guidelines and specialist advice for management of congenital diaphragmatic hernia.